CN114258394A - 一种致癌性融合激酶抑制剂的晶型及其应用 - Google Patents

一种致癌性融合激酶抑制剂的晶型及其应用 Download PDF

Info

Publication number
CN114258394A
CN114258394A CN202080058668.5A CN202080058668A CN114258394A CN 114258394 A CN114258394 A CN 114258394A CN 202080058668 A CN202080058668 A CN 202080058668A CN 114258394 A CN114258394 A CN 114258394A
Authority
CN
China
Prior art keywords
degrees
compound
formula
minus
plus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080058668.5A
Other languages
English (en)
Other versions
CN114258394B (zh
Inventor
王建非
孙继奎
杨广文
张杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Zaiming Pharmaceutical Co ltd
Original Assignee
Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcere Pharmaceutical Co Ltd filed Critical Simcere Pharmaceutical Co Ltd
Publication of CN114258394A publication Critical patent/CN114258394A/zh
Application granted granted Critical
Publication of CN114258394B publication Critical patent/CN114258394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种致癌性融合激酶抑制剂的晶型及其制备方法，并公开了其在制备治疗实体瘤相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202080058668.5A 2019-08-28 2020-08-27 一种致癌性融合激酶抑制剂的晶型及其应用 Active CN114258394B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910804019 2019-08-28
CN2019108040194 2019-08-28
CN2019108836226 2019-09-18
CN201910883622 2019-09-18
PCT/CN2020/111795 WO2021037156A1 (zh) 2019-08-28 2020-08-27 一种致癌性融合激酶抑制剂的晶型及其应用

Publications (2)

Publication Number Publication Date
CN114258394A true CN114258394A (zh) 2022-03-29
CN114258394B CN114258394B (zh) 2024-04-23

Family

ID=74684639

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058668.5A Active CN114258394B (zh) 2019-08-28 2020-08-27 一种致癌性融合激酶抑制剂的晶型及其应用

Country Status (4)

Country Link
US (1) US20220289765A1 (zh)
EP (1) EP4023648A4 (zh)
CN (1) CN114258394B (zh)
WO (1) WO2021037156A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN107207514A (zh) * 2014-12-15 2017-09-26 康联制药有限公司 稠环杂芳基化合物及其作为trk抑制剂的用途
CN111788205A (zh) * 2018-02-28 2020-10-16 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN107207514A (zh) * 2014-12-15 2017-09-26 康联制药有限公司 稠环杂芳基化合物及其作为trk抑制剂的用途
CN111788205A (zh) * 2018-02-28 2020-10-16 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其用途

Also Published As

Publication number Publication date
WO2021037156A1 (zh) 2021-03-04
CN114258394B (zh) 2024-04-23
EP4023648A4 (en) 2023-09-27
US20220289765A1 (en) 2022-09-15
EP4023648A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CN107382879B (zh) 一种嘧啶类化合物、egfr抑制剂及其应用
CN108558835B (zh) 一种氘代azd9291的晶型、制备方法及用途
WO2019228171A1 (zh) 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
CN109053592B (zh) 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
CN110590681B (zh) 一种新型喹唑啉酮类化合物及其制备方法和应用
EP4303220A1 (en) Crystal form of fluorine-substituted pyridopyrazole compound and preparation method therefor
CN114258394A (zh) 一种致癌性融合激酶抑制剂的晶型及其应用
CN112759564B (zh) 二芳基脲类化合物及其制法和药物用途
CN115448874A (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
TWI535724B (zh) 埃克替尼磷酸鹽的新晶型及其用途
CN114315837A (zh) 一种erk抑制剂的结晶形式及其制备方法
CN109438279B (zh) 一种克服egfr耐药突变的小分子化合物及其制备方法和用途
WO2019149090A1 (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
CN115368379B (zh) 一种含氰基取代的大环类化合物的晶型及其制备方法
AU2021407012B2 (en) CRYSTAL FORM OF CASEIN KINASE 1ε INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO2020221358A1 (zh) Wee1抑制剂化合物的晶型及其应用
CN114380800B (zh) 吡啶-嘧啶胺-苯并咪唑衍生物及其制备方法和用途
CN115109049B (zh) 含芳基脲结构的三嗪类化合物及其应用
CN109053732B (zh) 一种对氟取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
CN111848677B (zh) 一种alk激酶抑制剂化合物的晶型、制备方法及应用
CN109180676B (zh) 3,4,5-三甲氧基取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及制备方法
CN115232030A (zh) 芳基脲类化合物及其制法和药物用途
CN115304605A (zh) 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230725

Address after: 210032 No.99, Huakang Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Zaiming Pharmaceutical Co.,Ltd.

Address before: 210032 No.99, Huakang Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: SIMCERE PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant